🇺🇸 FDA
Patent

US 10258613

Compositions for treating retinal degeneration and methods of production and use thereof

granted A61KA61K31/085A61K31/09

Quick answer

US patent 10258613 (Compositions for treating retinal degeneration and methods of production and use thereof) held by The Board of Regents of the University of Oklahoma expires Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The Board of Regents of the University of Oklahoma
Grant date
Tue Apr 16 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 11 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K31/085, A61K31/09, A61K31/16, A61K31/17